A first-of-its-kind cancer treatment is generating unbridled excitement — but also underscoring intense concerns over pricing and value.

The drug, which is known as a CAR-T therapy, is expected to dramatically raise the chance of survival for children who have an aggressive form of leukemia and fail to respond to other treatments.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hats off to Trump for raiding his voice to lower the cancer drugsHope the company making the drugs follow the request

  • Sounds like Novartis have taken GcMAF, which the FDA closed down and intimidated and harassed doctors getting good results to then approve it for Novartis, at a difference in price in £ of £20,000 to £360,000. They are criminals that should be brought to justice. Why did the FDA do this? For money of course, what else!

  • Let’s cut down to the point. How much money is a child worth? That is the unethical question! People like Pierre Curie or Conrad Röntgen did not even file patents, as they deemed their Nobel Price inventions to valuable for man kind….. In our age and time they would be called fools I guess, or maybe our times are foolish?

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy